Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

anti-CD79A, DyLight 680, Clone: SPM549, Novus Biologicals™

Mouse Monoclonal Antibody

Manufacturer:  Novus BiologicalsSupplier Diversity Partner NBP234791FR

Catalog No. NBP234791FR


Add to cart

Description

Description

CD79A Monoclonal antibody specifically detects CD79A in Human samples. It is validated for Western Blot, Flow Cytometry, ELISA, Immunocytochemistry/Immunofluorescence, Immunoprecipitation, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen.
Specifications

Specifications

CD79A
SPM549
Western Blot, Flow Cytometry, ELISA, Immunocytochemistry/Immunofluorescence, Immunoprecipitation, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen
Purified
CD79A
A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of human CD79a protein.
44 kDa
0.1 ml
Adaptive Immunity, Cell Biology, Immunology
Primary
973
Human
ELISA, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot
DyLight 680
50mM Sodium Borate with 0.05% Sodium Azide
CD79a antigen, CD79A antigen (immunoglobulin-associated alpha), CD79a molecule, immunoglobulin-associated alpha, IGAB-cell antigen receptor complex-associated protein alpha chain, Ig-alpha, MB1, MB-1, MB-1 membrane glycoprotein, Membrane-bound immunoglobulin-associated protein, Surface IgM-associated protein
Mouse
IgG1 Kappa
Protein A purified
RUO
Store at 4C in the dark.
Monoclonal
A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
Documents
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit

For Research Use Only